NCT06997029 - A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | Biotech Hunter

Enrollment

234

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 14, 2028

Study Completion Date

December 14, 2028

Conditions

Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian Cancer

Interventions

DRUG

BMS-986500

Specified dose of specified days

DRUG

Palbociclib

Specified dose on specified days

DRUG

Fulvestrant

Specified dose on specified days

Trial Locations (15)

10016

NOT_YET_RECRUITING

Local Institution - 0011, New York

10021

NOT_YET_RECRUITING

Local Institution - 0012, New York

11042

NOT_YET_RECRUITING

Local Institution - 0016, New Hyde Park

14263

NOT_YET_RECRUITING

Local Institution - 0014, Buffalo

63110

RECRUITING

Washington University School of Medicine, St Louis

76104

NOT_YET_RECRUITING

Local Institution - 0018, Fort Worth

78229

RECRUITING

NEXT Oncology, San Antonio

80045

NOT_YET_RECRUITING

Local Institution - 0008, Aurora

92093

NOT_YET_RECRUITING

Local Institution - 0009, La Jolla

92663

NOT_YET_RECRUITING

Local Institution - 0010, Newport Beach

92835

NOT_YET_RECRUITING

Local Institution - 0003, Fullerton

94904

RECRUITING

Marin Cancer Care, Greenbrae

35294-3300

NOT_YET_RECRUITING

Local Institution - 0001, Birmingham

02215

NOT_YET_RECRUITING

Local Institution - 0006, Boston

03756

NOT_YET_RECRUITING

Local Institution - 0002, Lebanon